|
|
Doxorubicin is one of the most effective chemotherapeutic agents in the treatment of leukemia,
lymphoma and various solid tumors. Because of dose-dependent degenerative cardiomyopathy,
however, doxorubicin theraphy may be discontinued ineffectively early. Doxorubicin-induced conges-
tive heart failure carries a very poor prognosis since it is lethal in 60% of patients. Various methods
for evaluating the cardiotoxic effect have been employed such as EKG, systolic... |
